Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" oncology indications, providing new hope for patients with rare life-threatening diseases. In addition to ILC, Eleison is developing Glufosfamide, a Phase III drug candidate for the treatment of patients with pancreatic cancer, and is in discussions to acquire other promising candidates for rare cancers. Eleison was founded in 2009 and is headquartered in St. Petersburg, FL.